Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010980 | 0.81 | CHRNB2 (0.47) | DRD2CHRNB2CHRNA4SIGMAR1RECQL | |
| Hydrochloric Acid SCHEMBL31036735 | 0.76 | DRD2 (0.43) | DRD2DRD1CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL26620745 | 0.74 | HTR2C (0.42) | DRD2DRD1CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL13245795 | 0.74 | DRD2 (0.43) | DRD2DRD1CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL28081044 | 0.73 | DRD2 (0.42) | DRD2DRD1CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL24316298 | 0.72 | PNMT (0.50) | DRD2DRD1CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL30825518 | 0.72 | PNMT (0.46) | DRD2DRD1CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL19979180 | 0.72 | PNMT (0.46) | DRD2DRD1CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL13302986 | 0.71 | ALDH1A1 (0.47) | DRD1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL29858101 | 0.71 | ALDH1A1 (0.47) | DRD1CHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | GRM5, GRM1, GRM2 | DRD2 202/4885DRD1 193/4885CHRNB2 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.